Is PRME or PRTA more undervalued in 2026?

CirclFi compares Prime Medicine, Inc. (PRME) and Prothena Corporation plc (PRTA) using 13 institutional-grade valuation models. PRME has a Quality of Company score of 5.1/10 while PRTA scores 6.8/10.

Which is a better buy — PRME or PRTA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PRME and PRTA valuations compare?

PRME at $3.40 and PRTA at $9.98 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PRME vs PRTA Valuation Comparison 2026 — Intrinsic Value Analysis

PRME

Biotechnology

Prime Medicine, Inc.

Quality

5.1

out of 10

Value Trap

LOW

Price

$3.40

Last close

Models

9/13

Active

PRTA

Biotechnology

Prothena Corporation plc

Quality

6.8

out of 10

Value Trap

LOW

Price

$9.98

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	PRME Fair Value	PRME Upside	PRTA Fair Value	PRTA Upside
Bayesian DCF	Intrinsic	$0.85	-75.0%	$4.46	-55.3%
Earnings Power Value	Intrinsic	—	—	$6.84	-35.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.82	-75.9%	$0.40	-96.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PRME vs PRTA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PRME vs PRTA — Which Stock Is More Undervalued?

PRTA scores higher with a 6.8/10 quality rating vs PRME's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Prime Medicine, Inc. (PRME) and Prothena Corporation plc (PRTA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PRME currently trades at $3.40 with a QOC of 5.1/10, while PRTA trades at $9.98 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).